Glaukos Garners $108,000,000 New Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    26051 Merit Circle Laguna Hills, CA 92653 USA
  • Company Description
    Glaukos (NYSE: GKOS) is creating a new class of micro-bypass therapies to achieve sustainable, target intraocular pressures through the restoration of physiologic outflow, reduce the challenges and risks of glaucoma management associated with traditional therapies, and aid in the preservation of vision.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The principal purposes of this offering are to create a public market for our common stock, obtain additional capital, facilitate our future access to the public equity markets, increase awareness of our company among potential customers and improve our competitive position. We intend to use the net proceeds of this offering as follows: approximately $20.0 million to hire additional sales, marketing and customer service personnel and expand marketing programs both in the United States and outside the United States; approximately $15.0 million to fund clinical studies evaluating our pipeline of products under development and regulatory approvals for such products; approximately $15.0 million for the purchase of the glaucoma-related intellectual property and other assets from our affiliate DOSE Medical Corporation, or DOSE, pursuant to an asset purchase agreement dated as of July 10, 2014; and the remainder for working capital and other general corporate purposes.
  • M&A Terms

Trending on Xconomy